Search

everythinglearnresearchcommunity

for

Search:↓

Skin problems are common in kidney disease, with dry skin and itching in patients not on dialysis or on hemodialysis, and infections most common in transplant recipients.

Research on non-muscle invasive bladder cancer has increased, with the U.S. leading, and highlights effective treatments like BCG despite some side effects.

The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.

Peripheral treatments showed some improvement in sexual dysfunction, but central symptoms remain challenging.

Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.

Antibiotic resistance in children's UTIs, especially from E. coli, is rising due to misuse and easy access to antibiotics.

Genetic mutations can affect female sexual development, requiring personalized medical care.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.

Venous catheterization may help diagnose the cause of female hyperandrogenism when imaging is unclear.

The research found that measuring androgens in urine can give extra information about body metabolism and is linked to androgen levels in the blood, especially in young girls.

Finasteride exposure in pregnancy causes genital abnormalities in male rats.

Urinary PSA could be an early marker for enlarged prostate.

The document concludes that using gadolinium-based contrast agents during MRI can be linked to Nephrogenic Systemic Fibrosis in patients with severe kidney disease.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Early medical support for transgender youth is important for their health, with low regret for gender-affirming hormone use and a need for knowledgeable care providers.

Urinary stones increased in Wuwei, China, especially in males, suggesting the need for better screening and healthcare.

Genetic counselors should be culturally skilled and aware of transgender patients' unique health risks and needs.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Pediatric endocrinologists should provide early fertility counseling and preservation options to young patients at risk of infertility.

Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

Low testosterone increases kidney stone risk in men not on testosterone therapy.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.